Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.

DUBLIN, May 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark of the Evolut™ PRO+ TAVI System – the ...

Health Canada Issues Licence for Expanded Indications for Evolut TAVI Platform BRAMPTON, ON, Jan. 11, 2021 /CNW/ - Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) ― the world's ...

Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic ...

The data showed Evolut’s approach was not inferior to surgery when it came to a combined rate of death or disabling stroke after the procedure, with 4.3% for TAVR and 6.3% for surgery.

Medtronic's news bolsters the use case for Evolut, which is a particular boon, given that roughly 300,000 cases of severe aortic stenosis are diagnosed every year, according to University of ...

Medtronic plc reported positive interim results on the first 171 patients implanted with Evolut transaortic valve replacement (TAVR) devices in its OPTIMIZE PRO clinical trial. The postmarket, ...

Medical device major Medtronic plc MDT recently announced that it has received the FDA approval for its CoreValve Evolut PRO valve. It has been launched in the U.S. for the treatment of severe ...

Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict By Blake Brittain July 18, 202510:12 AM PDTUpdated July 18, 2025 ...

Medtronic plc MDT recently announced the commencement of a new real-world study - the Evolut R Forward Clinical trial - subsequent to reporting patients' enrollment in this multi-center, single ...

The FDA has approved Medtronic plc’s Evolut FX TAVR system for patients with symptomatic severe aortic stenosis. During Medtronic’s fiscal first quarter earnings call CEO Geoffrey Martha said the ...